CN111154766A - RHD-S68R mutant and detection method thereof - Google Patents
RHD-S68R mutant and detection method thereof Download PDFInfo
- Publication number
- CN111154766A CN111154766A CN202010047036.0A CN202010047036A CN111154766A CN 111154766 A CN111154766 A CN 111154766A CN 202010047036 A CN202010047036 A CN 202010047036A CN 111154766 A CN111154766 A CN 111154766A
- Authority
- CN
- China
- Prior art keywords
- rhd
- mutant
- gene
- seq
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
Abstract
The invention discloses an RHD-S68R mutant and detection thereof, wherein a wild type RHD gene is shown as SEQ ID NO: 1, and the mutant RHD gene is shown as SEQ ID NO: 2 is shown in the specification; the mutant RHD gene is shown as SEQ ID NO: 2 is shown in the specification; compared with the wild RHD gene, the mutant RHD gene is mutated from a base T to a base G at the 110 th position of the gene sequence; the upstream primer sequence of the specific primer for detecting the mutant is shown as SEQ ID NO. 3, and the downstream primer sequence is shown as SEQ ID NO. 4. The RHD-S68R mutant and the detection thereof can quickly and accurately detect the existence of the mutant gene doped in the gene library.
Description
Technical Field
The invention relates to the technical field of molecular biology, in particular to an RHD-S68R mutant and detection thereof.
Background
The Rh blood group is the most complex and polymorphic system of the human erythrocyte blood group system and is also the main erythrocyte blood group causing clinical transfusion reactions and severe neonatal hemolytic disease. More than 50 Rh blood group antigens are found, wherein RhD antigens have strong immunogenicity, are coded by RHD genes and are the key points of blood group research. Clinically, Rh blood group antigens are classified into two main types, namely RhD positive and RhD negative, according to whether D antigen is detected on the surface of an erythrocyte membrane.
Currently, the conventional method for detecting Rh blood group D antigen is to identify by serological saline method and indirect anti-human globulin test and absorption test. Serological techniques, however, have certain limitations. The results of some individuals when serotyped are difficult to determine due to disease or other factors; serological results of chronic long-term transfusion patients sometimes exhibit a phenomenon of "mixed visual field"; serological tests also fail to obtain correct results when samples cannot be obtained or when there are insufficient red blood cells or red blood cell samples, such as fetal blood grouping, forensic remains, etc.
The detection of RhD blood type by means of immunoserology depends mainly on the specificity of the anti-D antibodies and the amount of antigen expressed. Currently, with the development of molecular biotechnology, RhD mutants increase year by year, and the antigen expression amount and the gene mutation site thereof are different. The detection of the gene mutants mainly determines the Rh blood group D antigen genotype by a molecular biological method, has important clinical practical significance on making up the defects of a serology technology, and also has wide scientific research and application values.
Disclosure of Invention
The purpose of the invention is as follows: in order to overcome the defects in the prior art, the invention provides the mutant RHD204T > G allele of the RhD blood group antigen RHD-S68R and the detection method thereof, so as to quickly and accurately detect the existence of the mutant gene doped in a gene library.
The technical scheme is as follows: to achieve the above object, the RhD blood group antigen RhD-S68R mutant RhD204T > G allele of the present invention, the wild type RhD gene is shown as SEQ ID NO: 1, and the mutant RHD gene is shown as SEQ ID NO: 2 is shown in the specification; compared with the wild RHD gene, the mutant RHD gene is mutated from a base T to a base G at the 110 th position of the gene sequence; the amino acid sequence encoded by the wild type RHD gene is shown as SEQ ID NO: 5, the amino acid sequence encoded by the mutant RHD gene is shown as SEQ ID NO: 6, the amino acid sequence encoded by the mutant RHD gene is converted from serine S to arginine R at position 68 of the amino acid sequence thereof, as compared with the amino acid sequence encoded by the wild type RHD gene.
A specific primer for the detection of the RhD blood group antigen RhD-S68R mutant RhD204T > G allele, characterized in that: the sequence of the upstream primer of the specific primer is shown as SEQ ID NO. 3, and the sequence of the downstream primer is shown as SEQ ID NO. 4.
The beneficial effects of the invention are as follows: the RHD-S68R mutant and the detection thereof adopt a molecular biology method to detect the gene level, and can detect the existence of mutant genes doped in a gene library with high sensitivity and high precision; due to the difference of RHD genes among different nationalities, the gene is designed specially aiming at the newly discovered RHD204T > G allele in Chinese according to the molecular background of the RHD gene of Chinese. The invention not only has important clinical practical significance in making up the defects of the serology technology, but also has wide scientific research application value.
Drawings
FIG. 1 is a gel electrophoresis image of the RHD204T > G allele detection in the example;
FIG. 2 is a sequence chart of the RHD204T > G allelic mutation in the example.
Detailed Description
The present invention will be further described with reference to the accompanying drawings.
As shown in FIGS. 1 to 2, a RHD-S68R mutant and its detection, the mutant occurring at position 25284628 on chromosome 1, the gene being numbered NC-000001.11 (25272393-25330445) in the NCBl reference database GRCh38. p13. The partial DNA base sequences comprising the wild type of the present site in this database are listed here for reference, as shown in SEQ ID NO: 1 is shown in the specification; the mutant RHD gene is shown as SEQ ID NO: 2, respectively.
SEQ ID NO:1
CCTAAATCTCGTCTGCTTCCCCCTCGTCCTTCTCGCCATCTCCCCACCGAGCAGTTGGCCAAGATCTGACCGTGATGGCGGCCATTGGCTTGGGCTTCCTCACCTCGAGTTTCCGGAGACACAGCTGGAGCAGTGTGGCCTTCAACCTCTTCATGCTGGCGCTTGGTGTGCAGTGGGCAATCCTGCTGGACGGCTTCCTGAGCCAGTTCCCTTCTGGGAAGGTGGTCATCACACTGTTCAGGTATTGGGATGGTGGCTGGATCACTTCTGGGTCATAGAGGGAATGGACCCCGAAAGGACAGGTTCCAGAAGATCTGGGATATTG
SEQ ID NO:2
CCTAAATCTCGTCTGCTTCCCCCTCGTCCTTCTCGCCATCTCCCCACCGAGCAGTTGGCCAAGATCTGACCGTGATGGCGGCCATTGGCTTGGGCTTCCTCACCTCGAGGTTCCGGAGACACAGCTGGAGCAGTGTGGCCTTCAACCTCTTCATGCTGGCGCTTGGTGTGCAGTGGGCAATCCTGCTGGACGGCTTCCTGAGCCAGTTCCCTTCTGGGAAGGTGGTCATCACACTGTTCAGGTATTGGGATGGTGGCTGGATCACTTCTGGGTCATAGAGGGAATGGACCCCGAAAGGACAGGTTCCAGAAGATCTGGGATATTG
The mutant RHD gene is mutated from base T to base G at position 110 of the gene sequence, as compared with the wild type RHD gene. Because of the difference in amino acid sequences formed by the transcription of different gene sequences, the amino acid sequence formed by the transcription of the wild type RHD gene is shown as SEQ ID NO: 5 is shown in the specification; the amino acid sequence transcribed from the mutant RHD gene is shown in SEQ ID NO: 6 is shown in the specification; comparing the two transcribed amino acid sequences, wherein the amino acid change is represented in SEQ ID NO: the 68 th position of the 6 sequence is converted from serine S to arginine R.
SEQ ID NO:5
MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYF
SEQ ID NO:6
MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSRFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYF
The method for detecting the RhD blood group antigen RHD-S68R mutant RHD204T > G allele selectively amplifies a detection area of a target part containing a mutant gene by a gene amplification method, thereby detecting the existence of the mutant gene; the detection method comprises the following steps:
(1) extracting DNA in a sample to be detected;
(2) using the DNA as a template, and carrying out PCR reaction on a PCR primer designed aiming at a coding region near the RHD204T G mutant gene to obtain a PCR reaction product;
(3) measuring the nucleotide sequence composition of the PCR reaction product;
(4) comparing the nucleotide sequence to the sequence of the RHD wild type gene to determine whether there is a 204T → G mutation; the nucleotide sequence composition of the PCR reaction product can be used for sequencing the PCR reaction product through a sequencer.
The detection of the RhD blood group antigen RHD-S68R mutant RHD204T > G allele comprises the following specific steps:
(1) designing a primer: designing primers through Oligo 6.0 primer software according to RHD gene (sequence number: NC-000001.11) recorded by the GenBank of National Center for Biotechnology Information (NCBI), and finally determining 1 pair of specific oligonucleotide primer sequences, wherein the sequence of the upstream primer is shown as SEQID NO. 3 in Table 1; the sequence of the downstream primer is shown as SEQID NO. 4, and the length of the amplified product fragment is 172 bp;
TABLE 1 RHD204T > G allele detection primer sequences and reaction specificity
Note: the position of the exon base sequence referred to by the oligonucleotide primer sequence refers to the entire arrangement of 10 exons starting from the ATG start codon; the position of the base sequence of the intron in question refers to the single order of arrangement of each intron.
(2)RHD204T>Amplification of the G allele: the total volume of the reaction system is 50 mu L; wherein, the PCR reaction solution contains 10 mu L of PCR 5 Xbuffer solution and 5.0 mu L of DNA template,1U/. mu.L Taq polymerase 1.0. mu.L MgCl2The final concentration is 2.0mmol/L, the final concentration of dNTP is 200nmol/L, and the final concentrations of the specificity forward primer and the specificity reverse primer are both 200 nmol/L; adding sterilized double distilled water to the total volume of the reaction system to be 50 mu L; and (2) reacting the reaction system in a PCR instrument under the following reaction conditions: pre-denaturation at 95 ℃ for 5min, then denaturation at 94 ℃ for 30s in sequence, annealing at 60 ℃ for 40s, and extension at 72 ℃ for 1min for 32 cycles;
(3) RHD204T > G allele detection: and (3) carrying out electrophoresis on the amplified product obtained in the step (2) by using an agarose gel to detect whether the amplified product contains the target fragment.
Specifically, preparation of DNA template
The method adopts a purchased kit to extract the whole blood genome DNA, and comprises the following specific steps:
(1) taking one sterile 2.0mL centrifuge tube, and adding 1mL cell lysate;
(2) gently shaking the whole blood sample anticoagulated by EDTA until the whole blood sample is thoroughly mixed; then, adding 500 mu L of blood sample into the centrifuge tube containing the cell lysate, slightly pouring the centrifuge tube for 5-6 times, and uniformly mixing;
(3) incubate for 10 minutes at room temperature (during which the tube is inverted for 2-3 rounds of mixing);
(4) centrifuging at 12000rpm for 5 minutes at room temperature;
(5) the supernatant is removed as far as possible slowly by a liquid shifter, and the white substance at the interface of the two phases is not sucked out;
(6) mix vigorously using a vortex shaker (Votex) until the leukocytes are resuspended (10-15 seconds);
(7) to the resuspended cell solution was added 300. mu.L of the lysis solution. The solution was pipetted 5-6 times to lyse the leukocytes. At which point the solution should become very viscous. If cell clumps are visible after mixing, incubating the solution at 37 ℃ until clumps dissipate; if cell clumps remain visible after 1 hour of incubation, an additional 100. mu.L of lysis buffer was added and incubation at 37 ℃ repeated;
(8) adding 100 mu L of protein precipitation solution into the nuclear lysate, and violently shaking for 10-20 seconds by using a vortex oscillator;
(9) centrifuging at 12000rpm for 5 minutes at room temperature;
(10) transferring the supernatant to a corresponding number of 2.0mL centrifuge tube added with 300 μ L of room temperature isopropanol;
(11) gently invert to mix the solution until white linear DNA forms a precipitate;
(12) centrifuging at 12000rpm for 1min at room temperature;
(13) discarding the supernatant, adding room-temperature 70% ethanol with the volume equal to that of the sample, and slightly inverting the centrifuge tube for several times;
(14) the ethanol solution was removed as slowly as possible by pipette. Baking the centrifugal tube at 50 ℃ for 5-10 minutes to completely volatilize residual ethanol liquid as much as possible;
(15) adding 50-100 mu L of DNA solution into a centrifuge tube, and gently mixing uniformly;
(16) using 1% agarose gel electrophoresis to evaluate the DNA extraction effect, detecting the content by a Nanodrop nucleic acid instrument, quantifying to 20 ng/mu L, and storing at-20 ℃;
RHD204T > G allele detection technical scheme:
the instrument comprises the following steps: veriti 96 type PCR instrument, BIO-RAD Gel Doc XR + type Gel imager (Berle, USA), Gel electrophoresis instrument (Hex, Beijing).
Reagent: QIAamp DNA extraction kit (Qiagen, Germany); DNA Isolation Kit extraction Kit (Beijing PELFREEZ company); PCR buffer, dNTP, Taq enzyme (ABI, USA); the primers were synthesized by Shanghai Biometrics, Inc.
(1)RHD204T>Amplification of the G allele: total volume of reaction: 50 μ L, 10 μ L of PCR-containing 5 Xbuffer, 5.0 μ L of DNA template, 1.0 μ L of Taq polymerase (1U/. mu.L), MgCl2Final concentration 2.0mmol/L, dNTP final concentration 200nmol/L, and specificity upper and lower primer final concentration 200nmol/L, and adding sterilized double distilled water to total volume of 50 μ L. Reaction conditions are as follows: pre-denaturation at 95 ℃ for 5min followed by subsequent denaturation at 94 ℃ for 30 sec, followed by annealing at 60 ℃ for 40 sec and extension at 72 ℃ for 1min for 32 cycles.
(2) RHD204T > G allele detection: the amplified product obtained in step (1) was subjected to electrophoresis using 1.5% agarose gel to detect the presence or absence of the desired fragment. And observing and photographing the result by a gel imager, and displaying the PCR product as a single band after electrophoresis without a miscellaneous band, thus prompting that the PCR product is single and has no non-specific amplification. If the position of the stripe is in a position with proper size, the target segment is obtained. As shown in fig. 1, M: 50bp gradient molecular weight markers, 1: blank control, 2: wild-type control, 3: RHD204T > G mutant sample.
(3) And (3) purifying an amplification product: in this study, PCR products after Agarose Gel electrophoresis were purified and recovered using the Agarose Gel DNA purification kit from Takara, Inc., and prepared for sequencing.
(4) Sanger sequencing and result judgment: the purified PCR product was sequenced on an ABI3730 type fully automatic DNA sequencer. The sequencing results were aligned with the RHD wild-type Reference Sequence (NCBI Reference Sequence: NC-000001.11) and the results were reported as a function of the actual mutation. The gene mutation graph obtained by detection is shown in figure 2, and the arrow in the figure shows that the RHD gene shows g.25284628T > G mutation.
The above description is only of the preferred embodiments of the present invention, and it should be noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention and these are intended to be within the scope of the invention.
Sequence listing
<110> second people hospital of Anhui province (subsidiary hospital of higher specialty school of Anhui medical science, prevention and treatment hospital of occupational diseases of Anhui province)
<120> RHD-S68R mutant and detection thereof
<160>6
<170>SIPOSequenceListing 1.0
<210>1
<211>325
<212>DNA
<213>Homo sapiens
<400>1
cctaaatctc gtctgcttcc ccctcgtcct tctcgccatc tccccaccga gcagttggcc 60
aagatctgac cgtgatggcg gccattggct tgggcttcct cacctcgagt ttccggagac 120
acagctggag cagtgtggcc ttcaacctct tcatgctggc gcttggtgtg cagtgggcaa 180
tcctgctgga cggcttcctg agccagttcc cttctgggaa ggtggtcatc acactgttca 240
ggtattggga tggtggctgg atcacttctg ggtcatagag ggaatggacc ccgaaaggac 300
aggttccaga agatctggga tattg 325
<210>2
<211>325
<212>DNA
<213>Homo sapiens
<400>2
cctaaatctc gtctgcttcc ccctcgtcct tctcgccatc tccccaccga gcagttggcc 60
aagatctgac cgtgatggcg gccattggct tgggcttcct cacctcgagg ttccggagac 120
acagctggag cagtgtggcc ttcaacctct tcatgctggc gcttggtgtg cagtgggcaa 180
tcctgctgga cggcttcctg agccagttcc cttctgggaa ggtggtcatc acactgttca 240
ggtattggga tggtggctgg atcacttctg ggtcatagag ggaatggacc ccgaaaggac 300
aggttccaga agatctggga tattg 325
<210>3
<211>28
<212>DNA
<213>Homo sapiens
<400>3
cattggcttg ggcttcctca cctcgagg 28
<210>4
<211>25
<212>DNA
<213>Homo sapiens
<400>4
accatcccaa tacctgaaca gtgtg 25
<210>5
<211>179
<212>PRT
<213>Homo sapiens
<400>5
Met Ser Ser Lys Tyr Pro Arg Ser Val Arg Arg Cys Leu Pro Leu Trp
1 510 15
Ala Leu Thr Leu Glu Ala Ala Leu Ile Leu Leu Phe Tyr Phe Phe Thr
20 25 30
His Tyr Asp Ala Ser Leu Glu Asp Gln Lys Gly Leu Val Ala Ser Tyr
35 40 45
Gln Val Gly Gln Asp Leu Thr Val Met Ala Ala Ile Gly Leu Gly Phe
50 55 60
Leu Thr Ser Ser Phe Arg Arg His Ser Trp Ser Ser Val Ala Phe Asn
65 70 75 80
Leu Phe Met Leu Ala Leu Gly Val Gln Trp Ala Ile Leu Leu Asp Gly
85 90 95
Phe Leu Ser Gln Phe Pro Ser Gly Lys Val Val Ile Thr Leu Phe Ser
100 105 110
Ile Arg Leu Ala Thr Met Ser Ala Leu Ser Val Leu Ile Ser Val Asp
115 120 125
Ala Val Leu Gly Lys Val Asn Leu Ala Gln Leu Val Val Met Val Leu
130 135 140
Val Glu Val Thr Ala Leu Gly Asn Leu Arg Met Val Ile Ser Asn Ile
145 150 155 160
Phe Asn Thr Asp Tyr His Met Asn Met Met His Ile Tyr Val Phe Ala
165170 175
Ala Tyr Phe
<210>6
<211>179
<212>PRT
<213>Homo sapiens
<400>6
Met Ser Ser Lys Tyr Pro Arg Ser Val Arg Arg Cys Leu Pro Leu Trp
1 5 10 15
Ala Leu Thr Leu Glu Ala Ala Leu Ile Leu Leu Phe Tyr Phe Phe Thr
20 25 30
His Tyr Asp Ala Ser Leu Glu Asp Gln Lys Gly Leu Val Ala Ser Tyr
35 40 45
Gln Val Gly Gln Asp Leu Thr Val Met Ala Ala Ile Gly Leu Gly Phe
50 55 60
Leu Thr Ser Arg Phe Arg Arg His Ser Trp Ser Ser Val Ala Phe Asn
65 70 75 80
Leu Phe Met Leu Ala Leu Gly Val Gln Trp Ala Ile Leu Leu Asp Gly
85 90 95
Phe Leu Ser Gln Phe Pro Ser Gly Lys Val Val Ile Thr Leu Phe Ser
100 105 110
Ile Arg Leu Ala Thr Met Ser Ala Leu Ser Val Leu Ile Ser Val Asp
115 120 125
Ala Val Leu Gly Lys Val Asn Leu Ala Gln Leu Val Val Met Val Leu
130 135 140
Val Glu Val Thr Ala Leu Gly Asn Leu Arg Met Val Ile Ser Asn Ile
145 150 155 160
Phe Asn Thr Asp Tyr His Met Asn Met Met His Ile Tyr Val Phe Ala
165 170 175
Ala Tyr Phe
Claims (2)
1. A RhD blood group antigen RHD-S68R mutant RHD204T > G allele characterized by: the wild type RHD gene is shown as SEQ ID NO: 1, and the mutant RHD gene is shown as SEQ ID NO: 2 is shown in the specification; compared with the wild RHD gene, the mutant RHD gene is mutated from a base T to a base G at the 110 th position of the gene sequence; the amino acid sequence encoded by the wild type RHD gene is shown as SEQ ID NO: 5, the amino acid sequence encoded by the mutant RHD gene is shown as SEQ ID NO: 6, the amino acid sequence encoded by the mutant RHD gene is converted from serine S to arginine R at position 68 of the amino acid sequence thereof, as compared with the amino acid sequence encoded by the wild type RHD gene.
2. Specific primers for the detection of the RhD blood group antigen RhD-S68R mutant RhD204T > G allele according to claim 1 characterized by: the sequence of the upstream primer of the specific primer is shown as SEQ ID NO. 3, and the sequence of the downstream primer is shown as SEQ ID NO. 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010047036.0A CN111154766B (en) | 2020-01-16 | 2020-01-16 | RHD-S68R mutant and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010047036.0A CN111154766B (en) | 2020-01-16 | 2020-01-16 | RHD-S68R mutant and detection method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111154766A true CN111154766A (en) | 2020-05-15 |
| CN111154766B CN111154766B (en) | 2023-04-25 |
Family
ID=70563394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010047036.0A Active CN111154766B (en) | 2020-01-16 | 2020-01-16 | RHD-S68R mutant and detection method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111154766B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005075496A1 (en) * | 2004-02-06 | 2005-08-18 | Canadian Blood Services | A method for the simultaneous determination of blood group and platelet antigen genotypes |
| WO2012171990A1 (en) * | 2011-06-17 | 2012-12-20 | Progenika Biopharma, S.A. | Discrimination of blood type variants |
| CN103937806A (en) * | 2014-04-25 | 2014-07-23 | 无锡市第五人民医院 | Rh blood group DEL phenotype RHD838>A allele and detection method thereof |
| CN103966228A (en) * | 2014-04-25 | 2014-08-06 | 无锡市第五人民医院 | RH blood type DEL-type RHD93T>A allele and detection method thereof |
| CN109652559A (en) * | 2018-11-29 | 2019-04-19 | 江苏中济万泰生物医药有限公司 | A kind of mankind RhD blood group gene parting detection primer group and application |
| CN109913482A (en) * | 2019-04-24 | 2019-06-21 | 无锡市第五人民医院 | PIK3CA-I874R mutated gene and its application in Computer-aided Diagnosis of Breast Cancer |
-
2020
- 2020-01-16 CN CN202010047036.0A patent/CN111154766B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005075496A1 (en) * | 2004-02-06 | 2005-08-18 | Canadian Blood Services | A method for the simultaneous determination of blood group and platelet antigen genotypes |
| WO2012171990A1 (en) * | 2011-06-17 | 2012-12-20 | Progenika Biopharma, S.A. | Discrimination of blood type variants |
| CN103937806A (en) * | 2014-04-25 | 2014-07-23 | 无锡市第五人民医院 | Rh blood group DEL phenotype RHD838>A allele and detection method thereof |
| CN103966228A (en) * | 2014-04-25 | 2014-08-06 | 无锡市第五人民医院 | RH blood type DEL-type RHD93T>A allele and detection method thereof |
| CN109652559A (en) * | 2018-11-29 | 2019-04-19 | 江苏中济万泰生物医药有限公司 | A kind of mankind RhD blood group gene parting detection primer group and application |
| CN109913482A (en) * | 2019-04-24 | 2019-06-21 | 无锡市第五人民医院 | PIK3CA-I874R mutated gene and its application in Computer-aided Diagnosis of Breast Cancer |
Non-Patent Citations (3)
| Title |
|---|
| 吴大洲等: "1252T>G致新的弱D型血清学和分子生物学研究", 《中国输血杂志》 * |
| 杜文竹等: "1例Rh血型弱D15型变异体的分子基础", 《中国医学装备》 * |
| 王贞等: "广州地区人群中RHD* 960A突变型等位基因的鉴定及血型血清学与分子生物学特征分析", 《中国输血杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111154766B (en) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106521023B (en) | A kind of kit and method detecting Chinese HPFH and δ β-thalassemia | |
| CN103966228B (en) | A kind of Rh blood group DEL type RHD93T > A allelotrope and detection method thereof | |
| CN109913482B (en) | PIK3CA-I874R mutant gene and application thereof in auxiliary diagnosis of breast cancer | |
| CN106834287B (en) | SNP marker for detecting RhD negative phenotype | |
| CN103937806B (en) | A kind of Rh blood group DEL type RHD838G > A allelotrope and detection method thereof | |
| CN110029167B (en) | ERBB2-G519V mutant gene and application thereof in breast cancer auxiliary diagnosis | |
| CN111218453B (en) | RhD blood type antigen RHD-G353A mutant and detection | |
| CN111304211B (en) | RHD-T268A mutant and detection thereof | |
| CN111172297B (en) | RhD blood type gene RHD993C & gtT allele and application thereof | |
| CN111304332B (en) | Detection of breast cancer related gene BRCA2 site g.32336265G & gtT mutant | |
| CN106967808B (en) | Primer group for detecting RhD negative blood type and application thereof | |
| CN111304311B (en) | SNP marker for detecting O gene mutation in ABO blood group system | |
| CN112941205A (en) | RhD blood group gene RHD634G & gtA allele and detection | |
| CN111197091A (en) | Rh blood type DEL type RHD1073T & gtA allele and application thereof | |
| CN112940099B (en) | RhD-T163P mutant and detection thereof | |
| CN111154766B (en) | RHD-S68R mutant and detection method thereof | |
| CN105543400B (en) | The molecular marker of type-1 diabetes mellitus | |
| CN110055258B (en) | Breast cancer related gene ERBB2 site g.3939700G > A mutant and application thereof | |
| CN111154850A (en) | RHD939G & gtA allele and detection method thereof | |
| CN111154875A (en) | Breast cancer gene ERBB2 site g.39397711928A > G mutant and application thereof | |
| CN112063704A (en) | SNP (single nucleotide polymorphism) site related to A variant in ABO (anaerobic-baffled oxide) blood group system | |
| CN115011702B (en) | Allele of RhD blood type gene RHD56C & gtG and detection thereof | |
| CN116751786A (en) | Rh blood group D antigen RHD486C > A allele and detection primer thereof | |
| CN111154883A (en) | Breast cancer related gene PIK3CA site g.179220986A & gtT mutant and application thereof | |
| CN111139301B (en) | Breast cancer related gene ERBB2 site g.39397319C > A mutant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |